drugset / Trial / NCT01850680

Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis

NCT01850680

Phase 1 Completed 61 enrolled Sanofi Regeneron Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Objective: To assess the safety and tolerability of a single dose of subcutaneously administered sarilumab in Japanese patients with rheumatoid arthritis (RA) who are receiving concomitant treatment with methotrexate. Secondary Objective: To assess the pharmacokinetic profile of a single subcutaneous (SC) dose of sarilumab in Japanese RA patients.

Timeline

Start
2013-04
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody Subcutaneous
Background Methotrexate Small molecule Oral
Background folic acid Other / unclassified Oral

Indications